source
- Spyre Therapeutics cuts rheumatoid arthritis program after weak Phase 2 TL1A antibody resultsSpyre Therapeutics reported that its Phase 2 study of the anti‑TL1A antibody SPY072 in rheumatoid arthritis did not meet the efficacy expectations set earlier this year. The company said the data f…
- Profit motive highlighted as key to advancing women’s health research and boosting economic productivityExperts say that turning to the profit motive could spur investment in under‑funded women’s health areas such as endometriosis, osteoporosis and autoimmune disorders. They note a long history of r…